The Opportunity for Tamibarotene to Transform the Care of Newly Diagnosed Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression :: Syros Pharmaceuticals, Inc. (SYRS)

The Opportunity for Tamibarotene to Transform the Care of Newly Diagnosed Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression